Rick Simpson Oil (RSO) in Northwest Arctic Borough: The Complete Guide by OilWell Cannabis

Here in Northwest Arctic Borough, where the Arctic wind cuts across the tundra and the nearest specialist medical care might be a bush plane ride away, we understand what it means to search for alternatives when conventional medicine falls short. Whether you’re in Kotzebue facing months-long wait times for pain management, a veteran in Noatak struggling with PTSD after service, or a family in Shungnak navigating cancer treatment options hundreds of miles from Anchorage, you’ve likely heard whispers about Rick Simpson Oil. Maybe you saw it mentioned in an online patient forum. Maybe a friend in the healthcare system quietly suggested looking into it. Or maybe you’re simply exhausted from cycling through prescriptions that don’t work, and you’re seeking something – anything – that might offer genuine relief.

We are OilWell Cannabis, and we’ve been where you are. Our founder, Colin Valencia, built this company from the wreckage of a medical system that failed his dog Bentley, then failed him personally during his own battles with PTSD and benzodiazepine addiction. We don’t come from corporate boardrooms or pharmaceutical labs. We come from the school of hard-earned experience, from watching cannabinoids do what Western medicine couldn’t. We’re reaching out to Northwest Arctic Borough because we believe people in the Arctic deserve the same access to honest, evidence-based cannabis education that residents of Houston or Seattle take for granted.

This guide is everything you need to know about Rick Simpson Oil – its history, its evolution, the science behind every molecule in our formula, and exactly how it might fit into your life here in Northwest Arctic Borough. No hype. No snake oil. Just the most comprehensive, transparent RSO resource available anywhere.

Understanding Rick Simpson Oil: The Origin Story That Became a Global Movement

Who Was Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, oncologist, or research scientist. He was a power engineer and maintenance worker – a blue-collar tradesman whose path into cannabis advocacy began not with academic curiosity but with brutal personal suffering and a deep distrust of the medical system that failed him. This distinction matters for Northwest Arctic Borough readers because it mirrors the experience of so many in our region: when you’re told there’s nothing more that can be done, when prescriptions pile up without relief, when the system offers no alternatives, you’re left to find your own path.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused.

This resonates deeply in Northwest Arctic Borough, where many of us have faced healthcare providers who dismiss cannabis outright, even as we watch loved ones suffer from chronic pain, traumatic brain injuries from industrial accidents, or the long-term effects of living in a harsh environment. The Arctic’s extreme conditions – from seasonal darkness affecting mental health to physically demanding work in fishing, hunting, and mining – create unique healthcare challenges that often go unaddressed by mainstream medicine.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institutes of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study – originally intended to demonstrate harm – became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials. We mention this because we know cancer patients in Northwest Arctic Borough are searching for hope. We see you. We understand why this 1974 study still circulates in patient forums. But we’re committed to honesty: that mouse study is scientifically interesting, not proof of human efficacy.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. Important context: No independent medical verification of this outcome has ever been published. No biopsy confirmation or clinical follow-up exists in any peer-reviewed source. This personal experience became the origin story of Rick Simpson Oil, but it remains personal testimony, not medical evidence. It is historically significant as the catalyst for a global movement, but it cannot be evaluated using medical evidence standards.

For residents of Northwest Arctic Borough facing limited dermatology access, especially in villages like Kiana or Noorvik where a cancer diagnosis might mean immediate referral to Anchorage, we understand why Simpson’s skin cancer story carries weight. But we must be clear: anecdotal stories, however compelling, are not substitutes for clinical proof.

Simpson’s Crusade: Spreading the Oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community, charging nothing. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more.

In Northwest Arctic Borough, we know these conditions intimately. Diabetes rates in Alaska Native populations are among the highest in the nation. The physical demands of subsistence living, combined with limited access to fresh produce in remote villages, create a perfect storm for chronic inflammation and pain. Depression and insomnia plague our communities during the long winter darkness. Simpson’s list of conditions he claimed to address mirrors the health crisis unfolding across the Arctic.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. Within cannabis communities, it became foundational – for many, their introduction to concentrated cannabis oil as medicine. That documentary likely reached people in Northwest Arctic Borough through online forums, patient support groups, and word-of-mouth networks that transcend geography.

But Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and again in 2009, charging him with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, living in Croatia and the Netherlands, continuing his advocacy from abroad.

For Northwest Arctic Borough residents, this legal conflict history is relevant because it contextualizes the risks early cannabis advocates faced – and the legal safety we can now offer through Farm Bill-compliant products. Alaska may have legal cannabis, but the shadow of prohibition still lingers, especially for those who remember when possession meant serious criminal consequences.

The Traditional RSO Protocol: 60 Grams Over 90 Days

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver 60 grams of concentrated cannabis oil over approximately 90 days. For Northwest Arctic Borough residents searching “RSO dosing guide” or “how much RSO to take,” this is the protocol you’ve likely encountered online. We’re presenting it here in full detail because you deserve complete information, not summaries:

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice – roughly 10 to 15 milligrams of oil – taken three times per day (morning, afternoon, before bed). Total daily intake: approximately 30 to 45 milligrams.
• Weeks 2-5: Double the dose approximately every four days to build THC tolerance gradually. By the end of this period, reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5-12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, until all 60 grams are consumed.

For Northwest Arctic Borough residents, understanding the scale here is critical: 60 grams is an enormous amount of cannabis extract. At peak dosing, this protocol delivers approximately 600 to 900 milligrams of delta-9 THC daily – far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.

Administration Methods

• Oral (primary): Sublingual or swallowed. Simpson considered oral ingestion essential for systemic absorption.
• Topical (secondary): For skin cancers, apply directly to lesions, cover with bandage, change every 3-4 days.
• Inhalation (not recommended as primary): Simpson acknowledged inhalation for immediate symptom relief but maintained oral route was necessary for sustained therapeutic exposure.

Tolerance and Psychoactive Effects

Simpson claimed patients develop significant tolerance within 3-4 weeks, considered euphoric effects a temporary side effect, and recommended nighttime dosing initially to sleep through intense psychoactive effects. He warned against driving during titration.

In Northwest Arctic Borough, where winter roads are treacherous and summer construction seasons demand alertness, this impairment warning is particularly relevant. The nearest emergency services might be hours away – operating machinery or vehicles while impaired isn’t just illegal, it’s dangerous.

Post-Protocol Maintenance

After completing 60 grams, Simpson recommended 1-2 grams per month indefinitely for long-term health and cancer prevention.

Dietary and Lifestyle Recommendations

Simpson advocated reducing sugar, avoiding processed foods, and improving nutrition – general advice, not a formal protocol.

Critical Safety Context for Northwest Arctic Borough Residents

This protocol was designed by one person based on personal experience. It was not developed through clinical trials, dose-finding studies, or formal research. Several critical points apply:

• No controlled trial validation. Zero published randomized controlled trials, cohort studies, or well-documented case series evaluate this 60-gram/90-day protocol for any condition.
• Assumes crude, unstandardized material. Traditional RSO had no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing, 600-900 mg delta-9 THC daily carries serious risks: severe intoxication, anxiety, panic, tachycardia, hypotension, cannabis use disorder. These risks are well-documented in medical literature.
• Real risks at these doses. Consuming 600-900 mg THC daily is dangerous, especially in remote Arctic settings where medical help is far away.
• Oncology complexity. Patients with active cancer are medically complex. Using unregulated cannabis oil as primary treatment – potentially in place of proven therapies – introduces harm beyond the oil itself.

For Northwest Arctic Borough cancer patients considering this protocol: Please consult your oncology team at Maniilaq Health Center or Alaska Native Medical Center. RSO is not a substitute for chemotherapy, radiation, immunotherapy, or surgery. Delaying proven treatment for unproven alternatives can be life-threatening.

What Traditional RSO Actually Was

Traditional RSO was defined by Simpson’s method, not lab specifications:

Source Material: Single high-THC indica strains. No strain standardization – material varied by availability and growing season.

Extraction Solvent: Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. Naphtha may contain benzene, toluene, and other toxic compounds.

Extraction Process: Bucket, solvent, agitation, filtration, rice cooker evaporation, syringe storage. The rice cooker heat (60-80°C for naphtha, ~82°C for isopropyl) was sufficient to decarboxylate THCa to THC and destroy most terpenes.

Appearance: Nearly black, thick, tar-like oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid Profile: THC-dominant (60-90% estimated), fully decarboxylated, with minor cannabinoids at natural, uncontrolled ratios. No lab verification.

Terpene Content: Minimal to none – destroyed by solvent and heat.

Standardization & Testing: None. Every batch different. No COA, no cannabinoid quantification, no contaminant screening.

Residual Solvent Risk: Significant. Incomplete purging leaves toxic residues difficult to verify without lab testing.

For Northwest Arctic Borough residents who may encounter homemade RSO or products from unregulated sources: This is what you’re potentially getting – variable potency, toxic solvents, no testing. The Arctic’s remote nature makes it hard enough to access quality healthcare without adding contaminated cannabis products to the mix.

Simpson’s Claims vs. The Evidence Record

Simpson claimed RSO could cure cancer, diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, and more. These claims require honest evaluation.

What Simpson Was Not:
He had no formal training in medicine, oncology, pharmacology, or clinical research. He never designed, conducted, funded, or published a clinical trial. No peer review. His evidence base was personal experience and informal testimonials – no controls, no independent verification, no imaging confirmation, no long-term follow-up, no blinding.

What Preclinical Literature Shows:
In vitro and animal studies show THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines . Animal models show some tumor-growth inhibition. These findings generate legitimate scientific interest but have not translated to proven human cancer cures.

What Preclinical Literature Does NOT Show:
No human clinical trial has demonstrated RSO or any cannabis oil preparation cures cancer. The gap between in vitro/animal results and human outcomes is vast across all oncology research.

Institutional Positions:

• National Cancer Institute: Acknowledges cannabinoid anticancer research in labs and animals but does not endorse cannabis as cancer treatment .
• FDA: Has not approved any cannabis plant product for cancer. Only FDA-approved cannabinoid-related products are for specific other indications: Epidiolex (CBD) for certain seizure disorders; dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada: Never approved RSO or cannabis oil as cancer cure.
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea/vomiting, and HIV/AIDS appetite – not cancer cure [1].

What Simpson Got Right

Simpson drew attention to cannabinoids as serious biomedical research when most ignored them. He helped create conditions for the legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract. His advocacy – however scientifically imprecise – has historical significance.

What He Overstated

His cure claims exceeded the evidence. Encouraging patients to use RSO instead of proven cancer therapies carries genuine harm potential. Delayed or foregone treatment is a documented concern in alternative medicine. For Northwest Arctic Borough residents: Please, do not replace proven cancer treatment with RSO. Use it as a complementary approach if your oncology team agrees, but never as a substitute.

The Evolution: Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source Material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction Method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid Profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene Content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None – every batch different	Lab-tested with specific mg/mL targets
Lab Testing	Not performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual Solvents	Significant risk with naphtha	Controlled and tested
Dosing Precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product Formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa Preservation	No – fully decarboxylated	Yes – THCa included as separate ingredient at 1,500 mg
Evidence Approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

Multi-Cannabinoid Approach: Traditional RSO relied on whatever single strain was available. OilWell includes seven cannabinoids (CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC) because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene Preservation: Traditional RSO had essentially no terpenes. OilWell includes live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported at preclinical levels [20][21][23][24][25][26][27][28][29].

THCa as Separate Ingredient: Traditional RSO fully decarboxylated everything. OilWell preserves THCa at 1,500 mg because THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC [12].

Reduced Delta-9 THC Dominance: Traditional RSO was 60-90% delta-9 THC. OilWell uses only 90 mg delta-9 THC total, distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), CBN (750 mg), and CBC (750 mg).

Product Format Innovation: Simpson envisioned only oral oil. OilWell offers both 30 mL sublingual oil and 1-gram vape cartridge, each with format-specific formulations acknowledging different pharmacokinetic profiles [14].

Solvent Safety and Extraction Evolution

Traditional RSO’s naphtha or isopropyl alcohol extraction left toxic residues. Modern extraction uses food-grade ethanol or supercritical CO₂, allowing complete solvent removal and validated testing via headspace gas chromatography. This is one of the most straightforward improvements over traditional RSO.

The Decarboxylation Choice

Traditional RSO was always fully decarboxylated – all THCa converted to THC by rice cooker heat (60-80°C). OilWell’s sublingual formula preserves THCa at 1,500 mg as a distinct ingredient, giving you control over psychoactivity.

Three Usage Options:

1. Raw, no heat: All 1,500 mg stays as THCa – completely non-psychoactive, suitable for daytime use, work, driving, parenting.
2. Fully activated, home decarboxylation: Heat oil at 260°F (125°C) for 45-60 minutes in oven-safe glass. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC = ~1,405 mg total delta-9 THC, delivering psychoactive potency comparable to traditional illegal RSO.
3. Vape, auto-decarboxylation: Vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff.

Conversion Chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation (accounts for CO₂ molecule loss).

For Northwest Arctic Borough residents, this patient-controlled potency is transformative. You can use the raw form during the endless summer daylight when you need to stay alert for fishing or hunting, then decarboxylate for full potency during the dark winter months when sleep and pain relief become paramount.

About OilWell Cannabis: From a Dying Dog to Arctic Access

The Origin: Bentley’s Story

OilWell Cannabis began with a dog named Bentley in Houston, Texas. Bentley was more than a pet – he was family, a companion who stood by Colin through the toughest times of his childhood in McAllen, Texas, where he grew up in one of America’s most economically challenged and dangerous border regions.

When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. The pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” asked a rescue worker named Jessica.

Colin had cannabis experience – but it was recreational. He’d never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste – a specialized cannabinoid formula for pets. It was not a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up, walked over to Colin, and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect – dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Why This Matters for Northwest Arctic Borough: We know Arctic life is hard on bodies. The physical demands of subsistence hunting, fishing, and gathering – hauling nets through ice water, butchering caribou, chopping firewood in subzero temperatures – accelerate joint degeneration. The isolation and darkness impact mental health. Our elders face neurodegeneration with limited access to neurologists. Bentley’s story is our story: when conventional medicine says there’s nothing more to do, cannabinoids can offer hope grounded in real outcomes.

Colin’s Personal Journey: PTSD, Benzo Addiction, and Recovery

Colin also knows pharmaceutical dependence personally. He struggled with severe PTSD and benzodiazepine addiction – a story that will resonate with many veterans and first responders across Northwest Arctic Borough. When he decided to break free from Xanax, he did it cold turkey – a feat that is notoriously difficult and dangerous – using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD on an ongoing basis.

This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

Northwest Arctic Borough Context: We have veterans in Ambler and Kivalina dealing with PTSD from service. We have community members in Deering and Buckland navigating opioid addiction. We have elders in Selawik and Noatak facing chronic pain with limited access to pain clinics. Colin’s personal experience with pharmaceutical failure and cannabinoid success is your experience.

ABC13 Houston: Seven Features, Four Years, One Trusted Voice

Between September 2019 and April 2023, ABC13 Houston (KTRK) – the ABC affiliate serving America’s fourth-largest city – featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different reporters sought Colin out across those years. No other Houston cannabis operator appears with that frequency or breadth.

What This Means for Northwest Arctic Borough: Mainstream media validation from a major-market ABC affiliate is a credibility signal that transcends geography. While Northwest Arctic Borough may not have a local ABC affiliate, you can verify these stories online. This isn’t marketing – it’s independently produced, editorially controlled news coverage repeatedly identifying Colin as the most credible voice in the legal cannabis industry.

Featured Topics:

• Texas CBD business boom (2019) – Colin’s foundational quote: “I’m not trying to sell people snake oil… there’s enough research out there that people just need to know and try and have the best possible version”
• Decriminalization efforts and entrepreneur support (2021) – “Pain comes in a lot of different forms”
• Delta-8 THC investigation (2021) – Iconic exchange: “Maybe you want to get high” – radical honesty on mainstream TV
• COVID-19 vaccine giveaway (2021) – 1,000 caviar pre-rolls (~$35,000 in product) donated to encourage vaccination, coordinated with City of Houston
• Delta-8 ban impact (2021) – Colin proactively removed all products before enforcement, warned other operators
• Biden marijuana pardon (2022) – Colin revealed personal marijuana conviction history: “I would love to see people not get hurt for this anymore”
• Texas marijuana laws (2023) – “Renaissance” framing of current opportunity

Northwest Arctic Borough-Specific Takeaway: Colin’s personal conviction history, revealed in the 2022 feature, transforms the entire media record. Every quote about therapy, education, and not selling snake oil carries additional weight when you understand the person saying it has personally experienced the consequences of cannabis criminalization. This isn’t an outside entrepreneur – it’s someone who lived the worst of prohibition and built a legal business to prove the industry could operate with integrity.

OilWell’s Operating Philosophy: Four Core Principles

1. Accessibility Over Gatekeeping
No medical card required. Anyone age 21+ can purchase. We ship nationwide, including to Northwest Arctic Borough, and internationally where laws permit. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

2. Patient-Controlled Potency
THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric.

3. Open-Source Formulas
We publish our complete formulas publicly – every cannabinoid, every milligram, every percentage – so anyone who cannot afford our products can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace.

4. Evidence-Informed, Never Evidence-Overstating
The GENERAL KNOWLEDGE section of this document represents our commitment to honest education about what the science actually says. Simpson operated without peer-reviewed literature; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

The Science: Understanding Every Molecule in Our Formula

Research Methodology: How We Evaluate Evidence

Our evidence hierarchy prioritizes sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature when human data are sparse. This matters because the evidence base is not evenly distributed. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, and in vitro pharmacology [1]-[29].

For Northwest Arctic Borough readers, this methodology means we won’t make claims we can’t back up with verifiable research. When your healthcare options are already limited, the last thing you need is false hope or dangerous misinformation.

CBD (Cannabidiol): The Most Evidence-Developed Nonintoxicating Cannabinoid

Strongest Human Evidence:

• Epilepsy: Purified CBD has the most credible human evidence in seizure disorders, acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety: 2024 systematic review and meta-analysis of 316 participants across eight studies reported statistically significant anxiolytic signal, though authors stressed clinical sample remains limited [3].
• Pain: 2024 systematic review concluded pain literature is promising but heterogeneous, with trial quality limiting broad analgesic claims [4].
• Sleep: 2023 insomnia review found literature methodologically weak, with few objective sleep assessments [5].

Safety Concerns:
2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH flags diarrhea, sleepiness, appetite change, mood effects, liver abnormalities, and drug-drug interactions [1].

Northwest Arctic Borough Context: For residents taking multiple medications (common in communities with high rates of chronic disease), CBD’s interaction potential requires medical supervision. Always consult your provider at Maniilaq Health Center or your village clinic before adding CBD.

CBG (Cannabigerol): The “Mother Cannabinoid”

Evidence Profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].

Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids, interacting with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling – mechanistically interesting but not clinically established [7].

Research Areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, primarily pharmacology-led hypotheses or preclinical findings rather than mature human conclusions [7][8].

Caution: 2021 pharmacology review notes CBG is already commercially sold while evidence base remains thin – claims frequently outrun science [7].

Northwest Arctic Borough Context: CBG shows promise for neuroprotection, relevant for elders facing cognitive decline in communities like Noatak or Kiana where access to neurologists requires medical evacuation.

Delta-8 THC: Not Trivial, Not Proven Safe

Evidence Profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].

Comparative Pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity [9].

Public Health Literature: 2023 scoping review found delta-8 evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong human trials. Review noted reports of adverse consequences and emphasized regulatory/product-quality concerns [10].

Manufacturing Context: Recent chemistry review notes commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels [11].

Northwest Arctic Borough Context: Delta-8’s legal ambiguity matters here. While Alaska has legal cannabis, delta-8 exists in a gray area. We’ll be transparent: delta-8 is psychoactive, with incomplete safety characterization, and more manufacturing-quality uncertainty than many realize [9]-[11]. If you’re subject to workplace drug testing in the mining industry or with the North Slope Borough, delta-8 will likely trigger positive results.

THCa: The Legal Game-Changer

Evidence Profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence [12].

What It Is: THCa is the acidic precursor of THC, representing a large share of THC-related content in raw plant material. Key issue: THCa decarboxylates into THC during heating and can change during storage/processing [12].

Psychoactivity: THCa itself does not produce psychoactive effects associated with THC, but only if the molecule stays in acidic form and isn’t substantially decarboxylated [12].

Research Status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not established human outcomes [12].

Northwest Arctic Borough Context: This is the innovation that makes our product accessible. THCa’s legal status under the 2018 Farm Bill means you can legally purchase, possess, and transport our RSO, then activate it at home. For Arctic residents facing shipping restrictions and legal ambiguity, this framework provides clarity: our product is hemp-derived, contains less than 0.3% delta-9 THC at sale, and is legal to ship to Alaska.

Delta-9 THC: Strongest Evidence, Clearest Risks

Evidence Profile: Strongest human evidence of psychoactive cannabinoids, but also clearest adverse-effect burden [1][13]-[15].

Institutionally Best Supported: NCCIH identifies THC-containing medicines as relevant to chemotherapy-related nausea/vomiting, HIV/AIDS appetite/weight loss, and some MS/pain outcomes, while stressing many other uses remain uncertain [1].

Pain Evidence: 2022 systematic review found high THC-content products or comparable THC:CBD ratios may provide short-term pain benefit but increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].

Pharmacokinetics: Inhaled THC: effects within seconds-minutes, peaks ~15-30 minutes, lasts a few hours. Oral THC: later onset, later peak, longer duration – matters for both benefit and overconsumption risk [14].

Mental Health Risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings [15].

Broader Safety: Literature describes anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung injury [1][14][15].

Northwest Arctic Borough Context: The Arctic’s isolation amplifies these risks. If you experience severe anxiety or panic from high THC doses in a village like Kivalina or Shungnak, immediate medical help may be hours away. Our product’s dramatically lower delta-9 THC content (90 mg total vs. Simpson’s 600-900 mg/day) is a safety feature, not a limitation.

CBN: The Sleep Cannabinoid Myth

Evidence Profile: Weak human evidence; marketing has moved ahead of data [12][16][17].

What It’s Marketed For: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than marketing suggests [16][17].

Best Review for Sleep Claim: 2021 narrative review screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].

Broader Sleep Literature: 2024 updated review concluded overall cannabinoid sleep research still doesn’t match real-world use scale, and need for better-designed, adequately powered trials remains substantial [17].

Chemical Context: THCa review notes THC can degrade toward CBN under certain conditions, explaining why CBN is often discussed in aging/oxidized cannabis chemistry [12].

Northwest Arctic Borough Context: During the Arctic’s long winter darkness, sleep disorders are rampant. We include CBN at 750 mg (25-50 mg per 1-2 mL dose) because the preclinical signal is interesting and doses align with emerging literature, but we’re honest: the human evidence is not yet robust. We won’t overpromise sleep miracles.

CBC: The Emerging Neurogenic Cannabinoid

Evidence Profile: Emerging, intriguing, overwhelmingly preclinical or review-based [18][19].

Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting [18].

Older Literature: Review literature reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological or antiproliferative relevance – not yet strong evidence for patient-facing claims [19].

Safety Caution: 2024 CBC review explicitly notes over-the-counter CBC products are already sold despite little evidence establishing clinical efficacy or safety [18].

Northwest Arctic Borough Context: CBC’s potential relevance to seizure disorders may interest families in Noorvik or Deering dealing with epilepsy and limited access to neurologists. However, we emphasize: this is early-stage research, not proven therapy.

Terpenes: The Aromatic Dimension

Terpene claims need stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human cannabis studies. The 2024 entourage-effect review makes this crucial: terpene bioactivity is plausible but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene:

• Multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities – but most claims come from nonhuman/non-cannabis literature [21].
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens [22].

Myrcene:

• Described as having anxiolytic, antioxidant, anti-inflammatory, analgesic properties – but explicitly states human studies are lacking [23].
• Northwest Arctic Borough Context: Myrcene’s reputation as a “sedating terpene” is stronger than current human evidence supports. We include it for its aromatic complexity and potential synergy, not proven sedation.

Caryophyllene:

• Selective CB2 receptor agonist – unusual, making it especially relevant pharmacologically rather than just aromatically [24].
• Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions discussed, but human clinical confirmation limited [24].
• Northwest Arctic Borough Context: CB2 activation matters for inflammatory conditions common in Arctic populations (arthritis from physical labor, autoimmune issues). Caryophyllene is our strongest terpene candidate for cannabinoid-system significance.

Pinene:

• Antioxidant, anti-inflammatory, neuroprotective signals justify future study, but well-designed clinical trials lacking [25].
• Northwest Arctic Borough Context: Pinene’s forest-fresh aroma may resonate with residents who grew up in Alaska’s boreal forests. Scientifically, it’s interesting but not clinically proven for memory or attention effects.

Linalool:

• Discussed for stress, mood, brain-health pharmacology. 2021 review found enough preclinical signal to justify continued investigation, but lack of robust human trials [25].
• Separate literature discusses possible antidepressant mechanisms, but remains translational rather than definitive [26].
• Safety note: Oxidized linalool hydroperoxides are recognized allergens [22].

Humulene:

• Scoping review of 340 articles found broad preclinical evidence for anti-inflammatory effects, some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Northwest Arctic Borough Context: Humulene’s earthy, woody aroma complements the Arctic landscape. Its anti-inflammatory potential is valuable for residents dealing with chronic pain from physically demanding lifestyles.

Terpinolene:

• Screened 2,449 records, included 57 studies – concluded terpinolene has reported biological effects but evidence base dominated by in silico, in vitro, and animal studies, not human trials [28].
• Northwest Arctic Borough Context: Terpinolene’s piney, fruity, sparkling notes add sensory complexity but we present it as biologically interesting, not clinically proven.

Research Limits and Interpretation

Five Critical Rules:

1. Evidence is highly uneven. CBD and delta-9 THC support most detailed statements; others require more caution [1]-[29].
2. Whole-cannabis extract ≠ purified molecule ≠ semisynthetic ≠ terpene-only data. They are not interchangeable. Common error: letting evidence from one category stand in for another.
3. Minor cannabinoids and terpenes are commercially interesting because they’re underexplored, but that also means claims around them often become inflated.
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect real-world interpretation [1][10][11][14].
5. THCa chemistry changes with storage and heating. Storage/heating can convert acidic cannabinoids into neutral cannabinoids like THC [12].

Common Overstatements to Avoid

Overstatement: CBN is a clinically proven sleep cannabinoid.
More Accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].

Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
More Accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].

Overstatement: Terpenes in general have proven entourage effects in patients.
More Accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].

Overstatement: THCa is always nonpsychoactive.
More Accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].

Overstatement: Delta-8 THC is safe because it’s hemp-derived.
More Accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for Our Formulas

• Most evidence-developed actives: CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild; it’s psychoactive with less robust safety/efficacy characterization.
• THCa meaningfully changes with processing – not interpreted the same way raw vs. heated.
• CBG, CBN, CBC are scientifically credible but clinically immature compared to CBD/THC.
• Listed terpenes are likely highly relevant to aroma/flavor and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

OilWell RSO Products: Engineered for Arctic Needs

Two Formats, One Mission

We offer our RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles relevant to Northwest Arctic Borough lifestyles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, Delta-8 THC 6,000 mg, THCa 1,500 mg, Delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual (no separate delta-9 THC listed because THCa auto-decarbs at vaping temperature)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable by inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to Use Each Format: Arctic Lifestyle Guidance

Use Case	Recommended Format	Rationale for Northwest Arctic Borough
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset crucial when you’re hours from medical help
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration covers long Arctic nights or work days
Maximum bioavailability	Sublingual	13-19% absorption matters when every milligram counts
Portability/discretion	Vape	Compact for travel between villages, no measuring needed
Precise dosing control	Sublingual	Graduated dropper essential for titration in sensitive patients
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive – crucial for operating boats, snowmachines, working
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for sleep during dark winters

Condition-Specific Usage Context for Northwest Arctic Borough

Important Disclaimer: The following usage contexts are informed by cannabinoid research cited in this document and our formulation rationale. They are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT a substitute for professional medical care. These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

For Northwest Arctic Borough residents seeking culturally sensitive care: We encourage you to discuss cannabinoid use with your providers at Maniilaq Health Center or Alaska Native Medical Center. Traditional healing practices and modern medicine can complement each other when providers have complete information.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence: Delta-8 antiemetic [9], delta-9 nausea/vomiting [1][13], CBD anxiolytic buffering [3]

Northwest Arctic Borough Context: For residents traveling to Anchorage or Seattle for chemo, having a portable, fast-acting option (vape) for breakthrough nausea during travel is invaluable.

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual – anti-inflammatory without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual – combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence: CBD pain [4], delta-9 pain [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Northwest Arctic Borough Context: Chronic pain from physically demanding subsistence activities is endemic. Our multi-pathway anti-inflammatory approach (CBD, CBG, THCa, caryophyllene) addresses inflammation through different receptor systems simultaneously – more comprehensive than single-cannabinoid products.

Sleep Support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN – dosage level investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN – above threshold associated with reduced sleep disturbance
• Evidence: CBN sleep [16][17], cannabis and sleep review literature

Northwest Arctic Borough Context: Sleep disorders during winter darkness are a community health crisis. While CBN evidence isn’t robust, our inclusion at meaningful doses reflects emerging research. The Arctic’s extreme photoperiod disrupts circadian rhythms – a multi-cannabinoid approach may offer more benefit than single compounds.

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual – CBD and CBG address anxiety without impairment
• Nighttime: 1.0 mL sublingual – full profile including CBN for sleep architecture
• Evidence: CBD anxiety [3], CBG pharmacology [7][8], limonene entourage [20]

Northwest Arctic Borough Context: Seasonal affective disorder, PTSD among veterans, and general anxiety from isolation are significant community concerns. Non-psychoactive daytime options are crucial for maintaining functionality in remote villages where community responsibilities are constant.

General Titration Principle: Start Low, Go Slow

Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Arctic-Specific Consideration: The cold climate may affect metabolism and circulation. Starting low is especially important if you’re new to cannabinoids or have limited access to medical guidance.

Farm Bill Compliance and Legal Framework for Northwest Arctic Borough

The 2018 Farm Bill: Your Legal Protection

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle – 3 milligrams per milliliter – well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in Alaska.

THCa: The Legal Distinction That Changes Everything

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

Practical Significance for Northwest Arctic Borough Residents:
You can legally purchase, possess, and transport our RSO. You can then decarboxylate THCa into delta-9 THC at home by heating oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container.

Conversion Math:
1,500 mg THCa → ~1,315 mg delta-9 THC + existing 90 mg delta-9 THC = ~1,405 mg total delta-9 THC

This yields psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after legal purchase.

Customer-Controlled Activation for Arctic Life:

• Use raw during summer fishing season when you need to operate boats and stay alert
• Decarboxylate during winter darkness when sleep and pain relief are priorities
• The same legal product serves both needs – one purchase, multiple applications

Important Legal Notice for Alaska Residents

THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Alaska state laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal risk.

Alaska-Specific Guidance: Alaska has legal adult-use cannabis, but regulations around hemp-derived products can be complex. Our product meets federal hemp standards and Alaska’s alignment with those standards. However, you are responsible for verifying current local regulations. Contact us at (832) 416-2816 or [email protected] with questions.

Open-Source Formulas: Our Commitment to Arctic Accessibility

Why We Publish Everything

We publish our complete RSO formulas publicly – every cannabinoid, every milligram, every percentage – so anyone who cannot afford our products can source ingredients and make their own. This is a direct echo of Rick Simpson’s original ethos. He gave his oil away for free and taught people how to make it. He never patented his method. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

Northwest Arctic Borough Context: We understand that $129.99 for sublingual oil or $49.99 for vape cartridge may be significant in communities where cost of living is already extremely high and cash economies are common. By publishing our exact formulas, we ensure that if you have access to cannabinoid distillates and basic equipment, you can replicate our approach. This is our commitment to health equity in remote Arctic communities.

Colin’s 2019 Quote That Defines Us:
“I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Bentley’s CBD Golden Paste Recipe: The Original Open-Source Formula

Before we published RSO formulas, we published the CBD golden paste recipe that saved Bentley’s life. For Northwest Arctic Borough pet owners facing similar crises with aging sled dogs or companion animals, here it is:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size/needs; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and pepper. Stir until thoroughly mixed.
3. Cool, transfer to jar with lid. Refrigerate up to two weeks.
4. Add CBD oil to paste before giving to pet. Start low dose, gradually increase as needed.

Serving: Mix small amount with pet’s food once or twice daily. Monitor changes. Consult veterinarian with concerns.

Northwest Arctic Borough Context: For remote villages without veterinary access, this recipe may offer support for aging animals. However, always consult providers when possible. Dogs don’t respond to placebo – Bentley’s recovery was real cannabinoid medicine.

Delivery and Global Accessibility: Getting RSO to Northwest Arctic Borough

The Challenge of Arctic Logistics

We recognize that shipping to Northwest Arctic Borough is not like shipping to Houston. The Alaska Marine Highway doesn’t serve your communities. USPS Priority Mail may take longer than the advertised 2-3 days. Weather delays are real. We’ve designed our shipping infrastructure with these realities in mind.

Nationwide Shipping to Alaska

Shipping Options:

• USPS Priority Mail: 2-3 business days to Anchorage, then forwarding to Northwest Arctic Borough via air cargo or local delivery services. Expect 5-7 business days total to Kotzebue, longer to villages.
• FedEx/UPS Ground: 3-5 business days to Anchorage distribution centers, then additional time for final delivery. We recommend Priority Mail for more reliable tracking to remote Alaska.
• Temperature-Stable Packaging: Summer shipments to Alaska include insulation to protect product from heat during transit.
• Discreet Packaging: No cannabis branding visible – important for privacy in small communities.
• Tracking Provided: All orders include tracking numbers. We’ll work with you if weather delays occur.
• Signature-Required Option: Available for added security in villages where packages may be left at community pick-up points.

Northwest Arctic Borough-Specific Guidance:

• Kotzebue residents: Ship to your physical address or PO Box. USPS delivers to both.
• Village residents (Noatak, Kivalina, Shungnak, etc.): Ship to your community’s general delivery or local post office. Include your phone number so post office can contact you upon arrival.
• Weather delays: If your tracking shows packages held in Anchorage due to weather, this is normal. Product stability is not affected.

International Shipping: For Northwest Arctic Borough Residents with Family Abroad

Because our product contains less than 0.3% delta-9 THC at sale (hemp-derived), we can ship internationally where hemp laws permit. We’ve delivered to multiple continents.

International Package Contents:

• Full documentation
• Certificates of Analysis (COAs)
• Receipts for customs
• Customer Responsibility: You verify legality in your jurisdiction and accept all customs/legal risk. Contact us at (832) 416-2816 or [email protected] to discuss international shipping to your family’s location.

Northwest Arctic Borough Context: If you have family in Canada, Greenland, or other Arctic nations where hemp products may be legal, we can provide the documentation needed for customs clearance.

PANDEM1C SEO Technology: Making Our Arctic Presence Discoverable

Our proprietary PANDEM1C SEO system includes 14 million distinct geopolitical locations and 300+ AI models, driving organic search visibility across six continents. When someone in Kotzebue searches “RSO for chronic pain Alaska” or “hemp oil Northwest Arctic Borough,” our content is designed to be discoverable. You found this guide because that technology works.

Product Specifications: The Complete Formulas

RSO Sublingual Oil Formula

Cannabinoid	Amount (mg)
CBD	4,500
CBG	3,000
Delta-8 THC	6,000
THCa	1,500
Delta-9 THC	90
CBN	750
CBC	750
Total Cannabinoids	16,590 mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Carrier: Organic MCT oil
• Price: $129.99

Northwest Arctic Borough Value Calculation: At 40-60 doses per bottle, that’s $2.17-$3.25 per dose for a multi-cannabinoid, lab-tested, professional formulation. Compare to unreliable homemade extractions or single-cannabinoid products with 1/16th the cannabinoid content.

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 gram cartridge
• 510-thread universal battery compatibility
• Price: $49.99

Northwest Arctic Borough-Specific Use: The vape format is ideal for breakthrough pain episodes when you’re out on the land hunting or fishing and need immediate relief. The 1-2 minute onset can mean the difference between continuing your activity and having to call for emergency evacuation.

Terpene Profile: Sensory Experience Rooted in Arctic Nature

Both products contain the same seven live terpenes at 5%:

• Limonene – citrus-bright (evokes memory of imported citrus, rare treats in Arctic communities)
• Myrcene – herbal, earthy (complements the tundra’s natural aromas)
• Caryophyllene – pepper/spice (β-caryophyllene, the CB2 agonist)
• Pinene – forest-fresh (connects to Alaska’s boreal forests)
• Linalool – floral, lavender (soothing aroma for long winter nights)
• Humulene – earthy, woody (reminiscent of driftwood and tundra)
• Terpinolene – piney, fruity, sparkling (adds complexity)

Northwest Arctic Borough Connection: These terpenes aren’t just functional – they’re sensory anchors connecting the product experience to the Arctic environment you know. The pinene and humulene echo the scent of firewood and tundra plants. The linalool provides calm during stormy weather. We designed this profile to resonate with your world.

Competitive Comparison: Why OilWell for Northwest Arctic Borough

OilWell vs. Alaska Dispensary RSO

Most Alaska dispensaries sell THC-only RSO derived from marijuana, requiring you to:

• Travel to Anchorage or Fairbanks (expensive flights from Northwest Arctic Borough)
• Pay Alaska’s high cannabis taxes
• Accept a product with unknown minor cannabinoid content
• No option for non-psychoactive use

OilWell Advantages:

• Ships directly to Northwest Arctic Borough – no travel required
• Hemp-derived, Farm Bill compliant – no state cannabis taxes
• Seven defined cannabinoids – not just THC
• Patient-controlled potency – raw or activated
• Lower cost: $129.99 for 16,590 mg vs. Alaska dispensary prices often $60-80 for ~500 mg THC

OilWell vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No	Yes – via THCa decarboxylation
Price	$40-50	$129.99

Northwest Arctic Borough Value: You’re getting 16.5x the cannabinoid content for 2.6x the price, with a complete cannabinoid spectrum and patient-controlled activation.

Legal Compliance: Protecting Northwest Arctic Borough Customers

Age Requirements

21+ for all RSO products. We verify age at purchase.

THC Content Compliance

All products contain less than 0.3% delta-9 THC, Farm Bill compliant, hemp-derived.

FDA Disclaimers

Not evaluated by FDA. Not intended to diagnose, treat, cure, or prevent any disease. Consult healthcare provider before use. Individual results may vary.

Safety Warnings

• May cause drowsiness or impairment
• Do not operate vehicles or machinery while under influence
• Consult physician if pregnant or nursing
• Keep out of reach of children

Legal Responsibility

Buyer responsibility to check local laws. Company assumes no legal responsibility for customer’s use or decarboxylation decisions. Void where prohibited by law.

Alaska-Specific Note: While Alaska has legal cannabis, this product is hemp-derived and complies with federal law. You do not need a medical marijuana card to purchase. However, you are responsible for understanding current Alaska hemp regulations. Contact us if you have questions about legality in Northwest Arctic Borough specifically.

Full References: The Foundation of Our Claims

OilWell Research Base: 29 peer-reviewed citations across multiple journals and institutional sources. Unlike competitors who make claims without evidence, we show our work.

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024.

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH.

2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238.

3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049.

4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.

5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229.

6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752.

7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.

8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471.

9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933.

10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028.

11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.

12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130.

13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153.

14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.

15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440.

16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.

17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727.

18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.

19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.

20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543.

21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566.

22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12.

23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.

24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.

25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health. Front Psychiatry. 2021;12:583211.

26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092.

27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674.

28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768.

29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

Conclusion: A Promise to Northwest Arctic Borough

We are OilWell Cannabis. We don’t come from privilege or corporate boardrooms. We come from the same place many of you do – watching loved ones suffer, watching the medical system fail, and refusing to accept that there are no options. Our founder Colin built this company from the ground up, learning cannabis chemistry to save his dog, then using that knowledge to save himself from benzodiazepine addiction and PTSD.

We believe people in Northwest Arctic Borough deserve the same access to honest, evidence-based cannabis education that residents of any major city receive. We believe you deserve products that are:

• Transparent: Every ingredient published, every lab test available
• Accessible: Shipped directly to your village, no medical card required
• Flexible: Raw for daytime function, activated for nighttime relief
• Evidence-Based: 29 peer-reviewed citations backing every claim we make
• Safe: Solvent-free, lab-tested, Farm Bill compliant

We know the Arctic is unforgiving. Healthcare is hard to access. Costs are high. The darkness is real, both literal and metaphorical. But we also know that cannabinoids can help, and we’re here to provide them with the integrity, education, and community commitment that Rick Simpson envisioned – updated for the modern legal framework that makes it possible to serve you safely and legally.

Questions about RSO in Northwest Arctic Borough? Call us at (832) 416-2816 or email [email protected]. We’re real people who’ve lived these questions, and we’re here to help.

Ready to try OilWell RSO? Order directly from our website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Need the formula to make your own? It’s all published here. Use it. Share it. That’s why we made it open-source.

From Houston to the Arctic, from Bentley’s recovery to your own, we’re with you. The mission that started when a paralyzed dog got up and walked across the room continues now, reaching across a continent to the tundra of Northwest Arctic Borough, because nobody deserves to suffer when cannabinoids might help – and everyone deserves the truth about what they can and cannot do.

This content was created by OilWell Cannabis as a public educational resource for Northwest Arctic Borough residents. It is not medical advice. Please consult your healthcare provider before using any cannabinoid products.